26 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 17 Phase 4, 2 Not applicable, 2 Phase 2.
By phase and status
Follow Fundacion SEIMC-GESIDA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Effect of Extra Virgin Olive Oil Consumption on the Occurrence of Cardiovascular Events in Population Living With HIV
The patients must ingest 50 mL of extra virgin olive oil daily - HIV - Human Immunodeficiency Virus | Not applicable | Not yet recruiting | Fundacion SEIMC-GESIDA | 1324 | 2026-10-31 | 2026-08-12 |
GRAM NEGATIVES STUDY
Standard of care therapy - Multi-resistant Gram-negative Bacteria Cause Infection | | Recruiting | Fundacion SEIMC-GESIDA | 1500 | 2026-03-02 | 2026-08-06 |
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine. - HIV Infections, Fatty Liver Disease | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 63 | 2023-05-26 | 2025-07-18 |
Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities
BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo, Dovato 50Mg-300Mg Tablet + Biktarvy placebo - HIV Infections | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 84 | 2022-10-06 | 2025-07-18 |
Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)
Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY] - HIV Infections | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 101 | 2022-07-04 | 2026-06-30 |
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato] - HIV Infections | Phase 2 | Completed | Fundacion SEIMC-GESIDA | 167 | 2021-07-28 | 2026-09-09 |
DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:
Dolutegravir/Lamivudine as a single pill, Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill. - HIV-1-infection | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 554 | 2021-07-14 | 2025-07-18 |
Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia
Tocilizumab - COVID-19 | Phase 2 | Completed | Fundacion SEIMC-GESIDA | 495 | 2020-05-22 | 2021-06-02 |
Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain
Covid19 | | Completed | Fundacion SEIMC-GESIDA | 4035 | 2020-03-18 | 2023-07-03 |
A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection
Dual Therapy, Triple therapy - HIV Infections | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 141 | 2019-10-10 | 2024-10-01 |
Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
Bezlotoxumab Injection [Zinplava] - Clostridium Difficile Infection | | Completed | Fundacion SEIMC-GESIDA | 869 | 2019-10-01 | 2023-06-26 |
A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)
Symtuza® (TAF/FTC/DRV/c), ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c) - HIV Infections | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 78 | 2018-12-04 | 2022-06-22 |
A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017
HPV9v - HIV Infections | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 158 | 2018-10-15 | 2023-08-25 |
Spanish Cohort of Patients with HIV Infection Older Than 50 Years for the Study of Fragility and Physical Function
No interventions - HIV Infections, Frail Older Adults | | Unknown | Fundacion SEIMC-GESIDA | 802 | 2018-05-07 | 2024-09-03 |
A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression
Genvoya® - HIV Infections, Severe Immunosuppression | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 50 | 2018-04-13 | 2020-08-07 |
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
ELV/COBI/FTC/TAF, DTG/3TC/ABC + ELV/COBI/FTC/TAF - HIV Infections | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 39 | 2017-09-08 | 2020-02-05 |
A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
elbasvir/grazoprevir, Sofosbuvir, Ribavirin - HCV | Phase 4 | Withdrawn | Fundacion SEIMC-GESIDA | | 2017-07-01 | 2018-06-08 |
The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID
Screening for HCV in PWID and Linkage-To-Care - Hepatitis C, Drug Users | | Completed | Hospital Universitario Infanta Leonor | 529 | 2017-01-15 | 2019-09-13 |
Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice
HIV Infections | | Completed | Fundacion SEIMC-GESIDA | 762 | 2016-12-23 | 2020-02-05 |
Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection
HIV Infections | | Completed | Fundacion SEIMC-GESIDA | 467 | 2016-11-15 | 2017-05-17 |
Showing 20 of 31. Sign in to see all of them.
Conditions studied
HIV Infections (17) · Acquired Immunodeficiency Syndrome (2) · COVID-19 (2) · Hepatitis C (2) · Mycoses (2) · Clostridium Infections (1) · Coinfection (1) · Coronavirus Infections (1) · Disease Susceptibility (1) · Drug Misuse (1) · Fungemia (1) · Harm Reduction (1) · Lipodystrophy (1) · Liver Diseases (1) · Non-alcoholic Fatty Liver Disease (1)
Interventions
Lamivudine (4) · Emtricitabine (3) · Ritonavir (3) · dolutegravir (3) · Lopinavir (2) · Tenofovir (2) · bictegravir (2) · bictegravir, emtricitabine, tenofovir alafenamide, drug combination (2) · lopinavir-ritonavir drug combination (2) · tenofovir alafenamide (2) · Anidulafungin (1) · Cidofovir (1) · Darunavir (1) · Dual Anti-Platelet Therapy (1) · Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1)
Countries
Spain (30)
Top investigators
Asuncion Moreno, MD (1) · Belen Padilla, MD (1) · Carlos Cervera, MD (1) · Elena Sendagorta, MD (1) · Enrique Ortega (1) · Esteban Martinez, MD (1) · Esteban Ribera, MD (1) · Federico Pulido, MD (1) · Isabel Ruiz, MD (1) · Jordi Carratala, MD (1) · Jose Antonio Iribarren (1)
Results publications
PMID 23386261, PMID 26062881, PMID 26731755, PMID 26976872, PMID 29020293, PMID 31236601, PMID 33501995, PMID 36597036, PMID 39055703, PMID 40489982, PMID 41665101
NIH funding
2008 (2), 2014 (1)